Grant to support novel GABAA program targeting hippocampal overactivity that leads to neurodegeneration and cognitive decline in Alzheimer’s disease patients Baltimore, MD, September 13, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced…
Founder and CSO Michela Gallagher, PhD co-chaired a featured symposium, “The Two-Way Street Linking B-Amyloid, Tau and Neural Activity” and presented “Age-Related Network Dysfunction: Contributions of Neural Activity to Risk for Late Onset Alzheimer’s Disease.” Details available here.
Novel GABAA program targets hippocampal overactivity that leads to neurodegeneration and cognitive decline in Alzheimer’s disease patients Baltimore, MD, June 28, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the Company…
Baltimore, MD, February 17, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at the Neuroscience BioPartnering & Investment Forum. CEO Jerry McLaughlin will present a overview of AgeneBio‘s work in…
Baltimore, MD, February 2, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at BIO CEO & Investor Conference. CEO Jerry McLaughlin will present in the CNS/Neurological Track on Monday, February 8, at…
Trial to Study AGB101 to Determine if it Can Slow Progression of Symptoms Associated with aMCI and Prevent or Delay Onset of Alzheimer’s Dementia Baltimore, MD, December 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling…
Eli Lilly Alzheimer’s Drug Development Veteran Rounds Out Leadership Team for Phase 3 Ready AGB101 Baltimore, MD, December 8, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the appointment of Alzheimer’s drug…
Baltimore, MD, November 24, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present on a panel at the Future of Innovation in Medicine Conference: Incentives for New Medical…
Baltimore, MD, November 11, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present as a “Top Project to Watch: Most Licensable Products in Neuroscience” at the Informa Therapeutic…
AGB101 formulation suitable for use in the upcoming HOPE4MCI Phase 3 clinical trial to slow the progression of aMCI, the symptomatic pre-dementia stage of Alzheimer’s disease Baltimore, MD, November 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for…
